Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Promising Pipeline | Explore Geron's lead drug candidate, Rytelo, showing consistent efficacy in treating myelodysplastic syndromes and potential for broader applications |
Financial Crossroads | Delve into Geron's financial landscape, balancing strong liquidity with profitability challenges as it navigates towards a projected break-even point |
Market Momentum | Analyst price targets range from $4 to $9, reflecting optimism about Geron's growth potential despite recent stock volatility |
Strategic Expansion | Learn how EU approval could be a game-changer for Geron, potentially doubling its addressable market and enhancing its global pharmaceutical presence |
Metrics to compare | GERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGERNPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.0x | −0.4x | −0.5x | |
PEG Ratio | −0.14 | −0.01 | 0.00 | |
Price/Book | 3.1x | 2.3x | 2.6x | |
Price / LTM Sales | 7.2x | 5.4x | 3.3x | |
Upside (Analyst Target) | 233.3% | 312.4% | 42.8% | |
Fair Value Upside | Unlock | 22.5% | 6.5% | Unlock |